Phase 2 N=34 Pomalidomide for Chronic Graft-versus-Host Disease
Graft vs Host Disease · Graft-Versus-Host Disease
Primary: Overall Response at 6 Months — 0; 0; 7; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 Vibrotactile Stimulation in Parkinson's Disease
Parkinson's Disease
Primary: Number of Patients Reporting Any Adverse Effects — 0 Participants
Phase 2 N=706 Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Glycosylated Haemoglobin) — -0.97; -1.30; -1.65; -1.96 percentage of glycosylated haemoglobin — p=<0.0001
Phase 4 N=132 RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Cesarean Pain Relief
Cesarean Section · Pain, Postoperative
Primary: Total Oxycodone (mg) — 47.0; 65.0 mg
N/A N=80 Initial Performance of a Daily Disposable Contact Lens Featuring Molded Marks
Refractive Error
Primary: Incidence of Ocular Discomfort Device-related Adverse Events (AE) — 0; 1 Events
Phase 4 N=20 Effect of Samples on Acne Treatment With Epiduo® Gel
Acne Vulgaris
Primary: Adherence to Study Medication — 86; 71 percentage of doses
Phase 2 N=10 Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)
Inherited Epidermolysis Bullosa
Primary: Intra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds' — 8; 0 Wounds — p==0.008
Phase 2 N=27 Sorafenib and TRC105 in Hepatocellular Cancer
Hepatoma · Liver Neoplasms · Adenoma, Liver Cell
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg
Phase 2 N=124 Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects
Opioid Related Disorder
Primary: Participants With Treatment-Emergent Adverse Events (TEAEs) — 24; 15; 15; 15 Participants
N/A N=117 A Study to Evaluate the Effectiveness and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne.
Acne Vulgaris
Primary: Percent Change of Global Face Total Acne Lesion Count From Baseline — -44; -54 Percent change of acne lesion count
Phase 3 N=388 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Glycosylated Haemoglobin) — -1.47; -1.56; -0.00 Percentage of HbA1c — p=< 0.0001
Phase 2 N=207 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Brain and Central Nervous System Tumors
Primary: Phase I: Number of Patients With Dose-limiting Toxicity (DLT) — 2; 2; 2 Participants
N/A N=1,000 Prospective Trial to Compare the Clinical Efficiency of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy
Adenoma · Polyps · Colorectal Cancer
Primary: Detection Rate of Adenomas and Serrated Lesions — 147; 194 Participants
Phase 3 N=707 A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) Derived From Central Radiology Assessments: ITT Population — 62.5; 66.5 percentage of participants
Phase 2 N=130 Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
Thrombocytopenia Related to Chronic Liver Disease
Primary: Percentage of Participants Experiencing Response — 38.9; 31.3; 76.5; 6.3 Percentage of participants